Journal
BMC CHEMISTRY
Volume 17, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13065-023-00981-8
Keywords
Acute myeloid leukemia; FLT3 inhibitors; Indoles; Indole analogues
Categories
Ask authors/readers for more resources
FLT3 mutations are common in AML patients and are associated with poor clinical response. Several FLT3 inhibitors have been developed, but the overall survival rate in AML patients is still low. This review summarizes the indole-based FLT3 inhibitors and their chemotypes, mechanism of action, and interaction mode. It provides insights for future exploration of new therapies for FLT3-related AML.
Fms-like tyrosine kinase 3 (FLT3) mutation mechanisms are among the most common genetic abnormalities detected in about 30% of acute myeloid leukemia (AML) patients. These mutations are accompanied by poor clinical response, although all these progressions in identifying and interpreting biological AML bio-targets. Several small structured FLT3 inhibitors have been ameliorated to struggle against AML. Despite all these developments regarding these inhibitors, the Overall survival rate is about five years or more in less than one-third of diagnosed AML patients. Midostaurin was the first FDA-approved FLT3 inhibitor in 2017 in the United States and Europe for AML remedy. Next, Gilteritinib was an FDA-approved FLT3 inhibitor in 2018 and in the next year, Quizartinib was approved an as FLT3 inhibitor in Japan. Interestingly, indole-based motifs had risen as advantaged scaffolds with unusual multiple kinase inhibitory activity. This review summarises indole-based FLT3 inhibitors and related scaffolds, including FDA-approved drugs, clinical candidates, and other bioactive compounds. Furthermore, their chemotypes, mechanism of action, and interaction mode over both wild and mutated FLT3 target proteins had been judgmentally discussed. Therefore, this review could offer inspiring future perspectives into the finding of new FLT3-related AML therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available